• 제목/요약/키워드: metformin

검색결과 178건 처리시간 0.02초

2형 당뇨 마우스에서 솔잎 추출용액의 경구투여가 혈당조절에 미치는 영향 (Effects of Pine Needle Extract Oil on Blood Glucose and Serum Insulin Levels in db/db Mice)

  • 김미정;안진홍;최강호;이윤학;우경진;홍은경;정영신
    • 한국식품영양과학회지
    • /
    • 제35권3호
    • /
    • pp.321-327
    • /
    • 2006
  • 본 연구는 솔잎을 수증기 증류법으로 생산한 솔잎 추출용액을 2형 당뇨 마우스인 db/db mice에게 투여하여 솔잎 추출용액의 혈당강하 효과를 조사하고자 하였다. 이를 위해서 $30{\sim}40g$정도의 6주령 수컷 C57BL/Ksj(BL/Ls) homozygous diabetic(db/db) mice(SPF)를 음성대조군(corn oil), 솔잎 추출용액 저용량군(112.5 mg/kg), 고용량군(450 mg/kg) 및 양성대조군(metformin 150 mg/kg)의 4군으로 나누어 6주간 시험물질을 경구 투여하였다. 6주 사육기간 동안 혈당의 변화를 측정하기 위해 매주 1회씩 6시간 공복 시 미정맥으로부터 혈당을 측정하였으며, 6주 실험종료 후 모든 동물은 희생시킨 후 복대정맥에서 혈액을 채취하여 당화혈색소(HbAlc), 혈청 인슐린, C-peptide 및 leptin 농도 등을 측정하였다. 그 결과 다음과 같은 결론을 얻었다. 식이섭취량은 솔잎 추출용액 투여군에서 감소하는 경향을 보였으며, 양성대조군은 섭취량의 변화가 없었고, 1일 1마리당 평균섭취량은 고용량군이 음성대조군 및 양성대조군에 비하여 유의적으로 낮은 섭취량을 보였다. 체중은 군 간의 차이가 나타나지 않았으며, 간 무게와 상대적 간 무게는 음성대조군에 비하여 솔잎 추출용액 고용량군에서 유의적으로 높게 나타났다. 혈당은 솔잎 추출용액 고용량군에서 실험개시 3주부터 음성대조군에 비하여 유의적으로 감소하였으며, 최종 혈당은 저용량과 고용량군 모두 음성 대조군에 비해 유의적으로 낮아졌고, 용량 의존적인 경향성을 나타내었다. 당화혈색소의 함량 역시 솔잎 추출용액 고용량군에서 음성대조군에 비해 유의적이지는 않지만 낮은 경향을 보였다. 혈청 인슐린과 C-peptide농도는 솔잎 추출용액의 투여에 따른 차이가 나타나지 않아 솔잎 추출용액이 인슐린의 생성에 영향을 미치지는 않는 것으로 사료된다. 혈청 leptin 농도는 유의적이지는 않지만 음성대조군에 비해 솔잎 추출용액 투여군에서 높은 경향을 나타냈으며, 혈당과 음의 상관관계를 나타내고 있어 솔잎 추출용액의 혈당강하 효과의 작용기전으로 leptin과 관련된 인슐린 감수성에 영향을 미첬을 가능성이 있는 것으로 기대된다. 그러므로 본 연구에 사용한 112.5 mg/kg 및 450 mg/kg의 솔잎 추출용액은 6주 경구투여 시 혈당강하 효과를 나타냈으며, 인슐린의 농도에는 영향을 미치지는 않았다. 이러한 결과는 솔잎 추출용액의 혈당강하 효과의 작용기전이 인슐린의 감수성이나 저항성에 영향을 미쳤을 가능성이 있는 것으로 기대되며, 본 연구가 앞으로 솔잎 추출용액에 대한 다양한 연구를 활성화하는데 기여할 것으로 사료된다.

오적산 병용투여가 혈당강하 치료를 받고 있는 제2형 당뇨병 환자의 혈당에 미치는 영향 (A Retrospective Study on the Effect of the Co-Administration of Ojeok-san and Hypoglycemic Agents on Blood Glucose Levels in Type 2 Diabetes Mellitus)

  • 이민승;정수민;오승현;이한영;임형근;안영민;안세영;이병철
    • 대한한방내과학회지
    • /
    • 제42권1호
    • /
    • pp.40-52
    • /
    • 2021
  • Objective: This study was conducted to investigate the hypoglycemic effect and safety of Ojeok-san in patients with type 2 Diabetes Mellitus. Methods: We investigated type 2 diabetes mellitus patients at Kyung-Hee University Korean Medical Hospital who were administered Ojeok-san for at least one day between January 2012 and September 2020, basal characteristics and laboratory tests were reviewed retrospectively. The hypoglycemic effect of Ojeok-san was assessed by comparing fasting blood sugar (FBS) and two hours post-prandial plasma glucose (PP2) levels from before and after taking Ojeok-san. Subgroup analyses were conducted according to baseline hypoglycemic treatments and glycated hemoglobin levels (< or ≥6.5%). The safety of Ojeok-san was assessed by comparing levels of aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen, and creatinine. Results: After Ojeok-san administration, FBS and PP2 were significantly reduced to an average of 14.33 mg/dL and 27.67 mg/dL respectively. In the subgroup analysis, PP2 in patients receiving metformin mono therapy was significantly reduced to 28.67 mg/dL, and those receiving a dual therapy of metformin and DPP-4 inhibitor, it was significantly reduced to 32.33 mg/dL. In patients with glycated hemoglobin of lower than 6.5%, FBS was significantly reduced to 12.20 mg/dL, and both FBS and PP2 were significantly reduced, to 15.50 mg/dL and 40.00 mg/dL, respectively, in those with glycated hemoglobin levels of more than 6.5%. The safety profile showed no significant difference after Ojeok-san administration. Conclusions: Ojeok-san has significant hypoglycemic effects in patients with type 2 diabetes mellitus who are also taking hypoglycemic agents.

일개 한방병원에 내원한 다낭성 난소 증후군 환자의 특성 및 치료 분석 (Analysis of the Characteristics and Treatment of Polycystic Ovary Syndrome Patients in a Korean Medicine Hospital)

  • 박승혁;이진무;이창훈;장준복;황덕상
    • 대한한방부인과학회지
    • /
    • 제32권1호
    • /
    • pp.37-47
    • /
    • 2019
  • Objectives: The purpose of this study was to analyze the current characteristics and prescriptions of outpatients with Polycystic Ovary Syndrome (PCOS). Methods: We searched medical records from January 1, 2017 to December 31, 2017 and found out 31 patients who first visited with PCOS. Results: The average age of PCOS patients was $26.48{\pm}5.15years$ old, average height was $162.16{\pm}5.56cm$, average weight was $55.27{\pm}9.34kg$, and average BMI was $21.01{\pm}3.48kg/m^2$ A total of 24 patients who had received western treatment for PCOS in the past, 13 people received oral contraceptions, 4 hormones, 2 metformin, one hormone and metformin, also 4 people were treated for assisted reproductive technologies due to infertility. There were only two patients who combined Korean and Western treatments. The most common menstrual-related symptoms of PCOS patients were oligomenorrhea (48.4%) and dysmenorrhea (22.6%). Other symptoms were the highest in the cold symptoms (54.8%), followed by infertility (9.7%). The average number of patients visiting the hospital was $6.26{\pm}7.2$, with 22 (71.0%) coming from 1 to 5. The average treatment period for patients was $10.1{\pm}10.8weeks$, with 41.9% the largest for 1 to 4 weeks. Acupuncture (93.5%), moxibustion (96.8%) herbmed (96.8%) was treated to most PCOS patients. The most commonly used herbal medicines were Ongyeong-tang (35.5%), Ijin-tang-gami (19.4%), Dodam-tang-gami (12.9%), and Jogyeongjongok-tang-gami (12.9%). Conclusions: These results could be helpful to treat PCOS patients in Korean gynecologic clinical fields.

C57BL/6N db/db 생쥐에서 복분자 미숙과 에탄올 추출물의 항당뇨 효과 (Antidiabetic effects of unripe black raspberry ethanol extracts in C57BL/6N db/db mice)

  • 최혜란;이수정;류태호
    • 한국식품과학회지
    • /
    • 제54권4호
    • /
    • pp.391-397
    • /
    • 2022
  • 본 연구는 복분자 미숙과의 항당뇨 활성을 알아보기 위해 유전적 당뇨 질환 동물모델인 db/db 마우스에서 복분자 미숙과 50% 에탄올 추출물을 11주간 경구 투여한 후 당뇨병 개선 효과를 조사하였다. 체중 측정 결과, 정상대조군에 비하여 당뇨대조군의 체중이 45.9% 증가하였으나 복분자 미숙과 50% 에탄올 추출물을 투여한 실험군들의 체중 변화는 보이지 않았다. 시료 투여 11주 후 공복혈당을 측정했을 때 복분자 미숙과 50% 에탄올 추출물 투여군에서는 농도 의존적으로 혈당 상승이 억제되었으며, 복강내당능 시험을 통해 복분자 미숙과 50% 에탄올 추출물이 양성대조군과 유사한 경향으로 혈당을 감소시키는 것을 확인하였다. 혈중 중성지방 수치 역시 복분자 미숙과 50% 에탄올 추출물 투여군은 농도 의존적으로 중성지방의 농도가 감소되었고, 혈중 인슐린의 농도는 복분자 미숙과 50% 에탄올 추출물 투여군이 당뇨대조군보다 약간 높은 수준으로 나타났으나 군간 유의성은 없었다. 췌장의 병리조직학적 검사 결과, 당뇨대조군에서 인슐린을 분비하는 췌장의 베타세포로 이루어진 랑게르한스섬의 형태학적 손상이 나타났으며 복분자 미숙과 50% 에탄올 추출물 투여에 의해 손상이 억제됨으로써 랑게르한스섬의 면적 및 세포 수가 당뇨대조군에 비해 증가했음을 확인하였다. 또한 인슐린 항체를 이용하여 면역 염색을 통해 췌장 내 베타세포의 형태학적 구조를 확인해 보면 복분자 미숙과 50% 에탄올 추출물 투여군들에서 인슐린을 분비하는 랑게르한스섬 세포 수가 유의하게 증가되었음을 알 수 있었다. 따라서 위 결과를 종합해 볼 때 복분자 미숙과 50% 에탄올 추출물이 혈당 강하에 효과가 있으며, 이를 위한 목적으로 장기간 섭취했을 때 항당뇨에 도움이 될 것이라고 사료된다.

단삼투여가 고지방식이로 유발된 비만형 당뇨병 동물모델에 미치는 영향 (The Effects of Salvia miltiorrhiza on High Fat Diet-induced Obese Diabetic Mouse Model)

  • 최선욱;김동훈;최승범;박근희;김용성
    • 대한한방내과학회지
    • /
    • 제33권4호
    • /
    • pp.429-437
    • /
    • 2012
  • Objectives : Obesity is an important cause of diabetes, and lipotoxicity causes insulin resistance. In this study, we investigated the effects of Salvia miltiorrhiza on high fat diet-induced obese type 2 diabetic mouse models. Methods : Diabetes was induced in ICR male mouse (23~25 g) with Surwit's high fat, high sucrose diet. Mice were divided into 4 groups (n=10) of normal, control, Salvia miltiorrhiza, and metformin. After 8 weeks, body weight, OGTT, fructosamine, lipid profile, serum level of adiponectin and leptin, epididymal fat pad, liver weight and epididymal adipocyte size were measured. Results : Salvia miltiorrhiza significantly reduced oral glucose tolerance levels, fructosamine serum level, epididymal fat weight, and epididymal adipocyte size. Salvia miltiorrhiza also increased HDL-cholesterol, adiponectin and leptin serum levels. Conclusions : These results show that Salvia miltiorrhiza improves insulin resistance. Therefore we suggest that Salvia miltiorrhiza would be an effective treatment for obese type 2 diabetic patients.

C2C12 골격근세포에서 황기의 미토콘드리아 조절 작용 (The Effects of Astragali Radix Extracts on Mitochondrial Function in C2C12 Myotubes)

  • 송미영
    • 한방비만학회지
    • /
    • 제14권2호
    • /
    • pp.55-62
    • /
    • 2014
  • Objective: The prevalence of metabolic syndrome and type 2 diabetes is increasing worldwide. Mitochondrial dysfunction is known to be involved in insulin resistance and obesity, researches have been increasing highly. Astragali Radix extract (ARE) or its main components have been shown to perform comparably to insulin by significantly reducing blood glucose levels in animal models however, the influence on mitochondrial dysfunction are not well understood. Methods: ARE (0.2, 0.5 and 1.0 mg/ml) or metformin (2.5 mM) were treated in C2C12 after 6 day-differentiation. The expressions of adenosine monophosphate (AMP)-activated protein kinase (AMPK) and phosphorylation AMPK, peroxisome proliferators-activated receptror ${\gamma}$ coactivator $1{\alpha}$ ($PGC1{\alpha}$), nuclear respiratory factors 1 (NRF1), mitochondrial transcription factor (Tfam) and myosin heavy chain were detected with western blotting or polymerase chain reaction analysis. The morphological changes were also investigated. Results: ARE dose dependently increased phosphorylation of AMPK and respectively activated mRNA expressions of $PGC1{\alpha}$, NRF1 and Tfam which are mitochondrial biogenesis regulators. Furthermore, there were some morphologic differences of differentiated cells between ARE treatment and control. Conclusions: This study suggests that ARE has the potential to increase muscle mitochondrial function by activating AMPK and $PGC1{\alpha}$.

Effects of Purslane Extract on Obesity and Diabetes in High-Fat Diet-Induced Obese Mice

  • Kang, Kwang-Soon
    • 한국컴퓨터정보학회논문지
    • /
    • 제21권7호
    • /
    • pp.61-66
    • /
    • 2016
  • The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. In addition, obesity can induce type 2 diabetes (T2DM), hyperlipidemia and fatty liver disease. Recently, protective effect of purslane extract (PE) on obesity has been reported, but little is known about the role and mechanism of PE in obesity. This study aimed to evaluate the effect of PE on obesity and diabetes in obese mice. In addition, the effect of PE was compared with anti-obesity and diabetes drugs. High-fat diet (HFD)-induced obese mice were treated for 8 weeks with drugs as follows: PE, orlistat, metformin, voglibose or pioglitazone. While PE mixed with normal diet did not have any effects on BW in non-obese mice, PE mixed with HFD significantly reduced BW gain, insulin resistance, and glucose intolerance, without affecting food intake and appetite in obese mice. The effect was comparable to the effects of anti-obesity and diabetes drugs. Furthermore, PE significantly increased the activity of hepatocellular anti-oxidant enzymes, leading to protection of liver from oxidative stress in obese mice. These results suggest that PE treatment may be a useful tool for preventing obesity and complication of obesity.

An Update on Prader-Willi Syndrome with Diabetes Mellitus

  • Lee, Ji-Eun
    • Journal of mucopolysaccharidosis and rare diseases
    • /
    • 제2권2호
    • /
    • pp.35-37
    • /
    • 2016
  • Prader-Willi syndrome (PWS) often develops type 2 diabetes mellitus (T2DM) related to severe obesity. The prevalence of T2DM in adults with PWS (7-20%) exceeds greatly the prevalence in the general population (5-7%). It is uncommon for pre-pubertal children with PWS to develop overt diabetes or glucose intolerance. GH therapy and genotype did not influence the development of altered glucose metabolism. It has been assumed that T2DM in PWS develops as a consequence of morbid obesity and concomitant insulin resistance. However recent studies suggest the relationship between morbid obesity and T2DM development is more complex and appears to differ in PWS subjects compared to non-PWS subjects. PWS patients had relatively lower fasting insulin levels and increased adiponectin levels compared with BMI-matched obese control despite of similar levels of leptin. So PWS children may be protected to some extent form of obesity-associated insulin resistance. Although there's no data, it seems logical to approach diabetes management including weight loss and increased exercise, using similar pharmacological agents as with non-PWS obesity-related diabetes such as metformin or thiazolidinedione, with the introduction of insulin as required. On the other hand, several recent T2DM in PWS case reports suggest favorable outcomes using Glucagon-like peptide 1 (GLP-1) analog with regard to ghrelin reduction, control of glucose and appetite, weight loss and pre-prandial insulin secretion. The role of GLP-1 agonist therapy is promising, but has not yet been fully elucidated.

비만형 동물모델에서 복합 한약 추출물 CAPA의 비만 및 당대사 개선 효능 (The Mixed Herbal Extract, CAPA, Prevents Obesity and Glucose Intolerance in Obese Mice)

  • 송미영
    • 한방비만학회지
    • /
    • 제17권2호
    • /
    • pp.119-126
    • /
    • 2017
  • Objectives: This study investigated the effects of the mixed herbal extract from Cinnamomum cassia Blume, Atractylodes macrocephala Koidzumi, Pueraria lobata Benth, and Aconitum carmichaeli Debx (CAPA) on obesity and glucose tolerance in obese mice. Methods: Animals were divided in 6 groups, normal diet, high fat diet (HFD), HFD with CAPA 100 mg/kg (CAPA 100), CAPA 300 mg/kg (CAPA 300), and metformin 200 mg/kg or lorcaserin 10 mg/kg as positive controls, and treated for 16 weeks. Body weight, food intake, fasting blood glucose, and body temperature were checked every week and then organs, blood serums were collected after treatment. The oral glucose tolerance test was also carried out after treatment. Results: Compared to HFD, CAPA extract treated mice showed significant decreases in body weight, adipose tissue weight, lipid accumulations in liver and serum lipid levels without a reduction of food intake. And fasting glucose and glucose tolerance were all improved in the CAPA treated mice. Conclusions: Our results suggest that CAPA extract can prevent diet induced obesity and glucose intolerance without a reduction of energy intake in obese mice.

Update on polycystic ovary syndrome

  • Kim, Jin Ju
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제48권3호
    • /
    • pp.194-197
    • /
    • 2021
  • Polycystic ovary syndrome (PCOS) is a common disorder in reproductive-age women. In 2018, an international evidence-based guideline announced recommendations spanning a wide range of issues on the assessment and management of PCOS. From the 166 recommendations, the present study reviews those that are of particular clinical relevance for daily practice and introduces other relevant studies that have been published since the global guideline. The 2018 guideline increased the antral follicle count cutoff for the diagnosis of PCOS from 12 to 20 when using a high-frequency probe. Hirsutism was defined as having a score of ≥4-6 based on a lower percentile of 85%-90% or cluster analysis, which was lower than the traditionally used 95th percentile-based cutoff. The diagnosis of PCOS in adolescents is challenging, and irregular menstruation was defined carefully according to years from menarche. The use of ultrasonography for the diagnosis of PCOS was restricted to those 8 years after menarche. As medication for non-fertility indications, combined oral contraceptives are the first-line drug. Metformin, in addition to lifestyle modifications, should be considered for adult patients with a body mass index ≥25 kg/m2 for the management of weight and metabolic outcomes. An aromatase inhibitor is the recommended first-line medication for ovulation induction, a subsequent individual patient data meta-analysis also reported the same conclusion. Whether the new global guideline will be fully adopted by many specialists and change clinical practice is open to question. Further studies are needed to better understand and manage PCOS patients well.